Published in Hum Mol Genet on August 01, 1995
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther (2008) 2.69
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther (2011) 2.06
Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol (1996) 1.79
Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med (1996) 1.56
Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet (2006) 1.44
Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J Gene Med (2006) 1.36
Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am J Pathol (2008) 1.33
In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther (2010) 1.33
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech (2015) 1.30
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta (2006) 1.25
Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. Hum Mol Genet (2004) 1.25
Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther (2010) 1.20
Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a "mild Becker" phenotype. J Cell Biol (1996) 1.16
Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice. PLoS One (2010) 1.14
Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J (2013) 1.11
Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One (2012) 1.10
How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum Mol Genet (2015) 1.07
Gene therapy in large animal models of muscular dystrophy. ILAR J (2009) 1.05
Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene. Proc Natl Acad Sci U S A (1996) 1.04
Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice. J Biomed Biotechnol (2012) 0.97
AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Ann Clin Transl Neurol (2015) 0.95
Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice. BMC Biotechnol (2008) 0.90
Duchenne muscular dystrophy gene therapy in the canine model. Hum Gene Ther Clin Dev (2015) 0.86
Quadriceps myopathy caused by skeletal muscle-specific ablation of β(cyto)-actin. J Cell Sci (2011) 0.85
Critical variables in the conversion of marrow cells to skeletal muscle. Blood (2005) 0.85
The carboxy-terminal third of dystrophin enhances actin binding activity. J Mol Biol (2011) 0.85
Preclinical studies with umbilical cord mesenchymal stromal cells in different animal models for muscular dystrophy. J Biomed Biotechnol (2011) 0.82
Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors. Curr Gene Ther (2012) 0.81
Dystrophin quantification: Biological and translational research implications. Neurology (2014) 0.81
piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. Nucleic Acids Res (2015) 0.79
Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells. J Clin Invest (1997) 0.79
Human cytomegalovirus IE1 promoter/enhancer drives variable gene expression in all fiber types in transgenic mouse skeletal muscle. BMC Genet (2000) 0.79
Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy. Nutrients (2015) 0.77
Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs. Mol Ther (2016) 0.75
Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy. Expert Opin Orphan Drugs (2015) 0.75
Uniform low-level dystrophin expression in the heart partially preserved cardiac function in an aged mouse model of Duchenne cardiomyopathy. J Mol Cell Cardiol (2016) 0.75
Progress toward Gene Therapy for Duchenne Muscular Dystrophy. Mol Ther (2017) 0.75
Functional correction of dystrophin actin binding domain mutations by genome editing. JCI Insight (2017) 0.75
Membrane organization of the dystrophin-glycoprotein complex. Cell (1991) 6.64
Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature (1992) 6.37
Structural evidence for direct interaction between the molecular components of the transverse tubule/sarcoplasmic reticulum junction in skeletal muscle. J Cell Biol (1988) 6.30
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol (1993) 5.73
Purified ryanodine receptor from rabbit skeletal muscle is the calcium-release channel of sarcoplasmic reticulum. J Gen Physiol (1988) 4.56
Calcium channel beta-subunit binds to a conserved motif in the I-II cytoplasmic linker of the alpha 1-subunit. Nature (1994) 4.34
The naming of voltage-gated calcium channels. Neuron (1994) 4.31
Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature (1990) 4.23
Monoclonal antibody to a plasma membrane antigen of neurons. Proc Natl Acad Sci U S A (1979) 4.09
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) (2002) 3.87
Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci (1999) 3.77
A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron (1994) 3.57
Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med (2000) 3.50
Further segregation analysis of the fragile X syndrome with special reference to transmitting males. Hum Genet (1985) 3.42
Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42
Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel. Science (1988) 3.38
Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol (1997) 3.32
The mouse stargazer gene encodes a neuronal Ca2+-channel gamma subunit. Nat Genet (1998) 3.31
Purified ryanodine receptor from skeletal muscle sarcoplasmic reticulum is the Ca2+-permeable pore of the calcium release channel. J Biol Chem (1987) 3.25
The marker (X) syndrome: a cytogenetic and genetic analysis. Ann Hum Genet (1984) 3.17
Nomenclature of voltage-gated calcium channels. Neuron (2000) 3.09
Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature (1991) 3.03
An autosomal transcript in skeletal muscle with homology to dystrophin. Nature (1989) 2.91
Inhibitor of neurite outgrowth in humans. Nature (2000) 2.89
Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature (1992) 2.76
Smith-Fineman-Myers syndrome in two brothers. Am J Med Genet (1991) 2.70
Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet (1997) 2.69
Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J Cell Biol (1991) 2.68
Molecular basis of muscular dystrophies. Muscle Nerve (2000) 2.65
Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature (1993) 2.63
Direct binding of G-protein betagamma complex to voltage-dependent calcium channels. Nature (1997) 2.60
Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell (1999) 2.57
Transformation of Aspergillus nidulans by the orotidine-5'-phosphate decarboxylase gene of Neurospora crassa. Biochem Biophys Res Commun (1983) 2.56
Ryanodine receptor of skeletal muscle is a gap junction-type channel. Science (1988) 2.56
Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Curr Biol (1999) 2.55
Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med (1999) 2.50
The ryanodine receptor/Ca2+ release channel. J Biol Chem (1993) 2.50
Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut (2009) 2.50
Structural mosaicism on the submicron scale in the plasma membrane. Biophys J (1998) 2.50
Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol (1998) 2.44
X-linked mental retardation, macro-orchidism, and the Xq27 fragile site. J Pediatr (1980) 2.41
Staining of the Ca2+-binding proteins, calsequestrin, calmodulin, troponin C, and S-100, with the cationic carbocyanine dye "Stains-all". J Biol Chem (1983) 2.40
A role for dystroglycan in basement membrane assembly. Cell (1998) 2.36
Abnormal expression of dystrophin-associated proteins in Fukuyama-type congenital muscular dystrophy. Lancet (1993) 2.33
Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. Neuron (1991) 2.30
Activation of the FGF receptor underlies neurite outgrowth stimulated by L1, N-CAM, and N-cadherin. Neuron (1994) 2.29
Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol (1999) 2.29
Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J (2002) 2.26
Neuropilin-2 is required in vivo for selective axon guidance responses to secreted semaphorins. Neuron (2000) 2.25
Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III (1994) 2.22
Heterozygous expression of X-linked mental retardation and X-chromosome marker fra(X)(q27). N Engl J Med (1980) 2.21
Orientation of cell-surface antigens in the lipid bilayer of lymphocyte plasma membrane. Nature (1977) 2.18
The Ca2+-release channel/ryanodine receptor is localized in junctional and corbular sarcoplasmic reticulum in cardiac muscle. J Cell Biol (1993) 2.18
Bronchoalveolar lavage findings suggest two different forms of childhood asthma. Clin Exp Allergy (1997) 2.17
Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet (1995) 2.16
Prevalence of HIV infection in patients attending an inner city accident and emergency department. BMJ (1994) 2.15
Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol (1997) 2.13
Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron (1998) 2.11
Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound Obstet Gynecol (2013) 2.11
Dystrophin-glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. J Cell Biol (1991) 2.10
Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet (1998) 2.07
The brain ryanodine receptor: a caffeine-sensitive calcium release channel. Neuron (1991) 2.05
Isolation, characterization, and localization of the inositol 1,4,5-trisphosphate receptor protein in Xenopus laevis oocytes. J Biol Chem (1992) 2.05
Dual function of the voltage-dependent Ca2+ channel alpha 2 delta subunit in current stimulation and subunit interaction. Neuron (1996) 2.04
Induction of calcium currents by the expression of the alpha 1-subunit of the dihydropyridine receptor from skeletal muscle. Nature (1989) 2.04
Maturation and maintenance of the neuromuscular synapse: genetic evidence for roles of the dystrophin--glycoprotein complex. Neuron (2000) 2.04
Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol (2001) 2.03
Development of a high-frequency transforming vector for Aspergillus nidulans. Gene (1985) 2.03
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. Plast Reconstr Surg (1999) 2.02
Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Science (1998) 2.02
The biochemistry and molecular biology of the dihydropyridine-sensitive calcium channel. Trends Neurosci (1988) 1.98
Alternative splicing generates a secreted form of N-CAM in muscle and brain. Cell (1988) 1.97
A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci U S A (1999) 1.96
Further characterization of light and heavy sarcoplasmic reticulum vesicles. Identification of the 'sarcoplasmic reticulum feet' associated with heavy sarcoplasmic reticulum vesicles. Biochim Biophys Acta (1980) 1.96
X-linked mental retardation without physical abnormality: Renpenning's syndrome. Dev Med Child Neurol (1971) 1.95
CAM-FGF receptor interactions: a model for axonal growth. Mol Cell Neurosci (1996) 1.95
Ca2+ channel regulation by a conserved beta subunit domain. Neuron (1994) 1.92
Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol (2000) 1.92
A third novel locus for primary autosomal recessive microcephaly maps to chromosome 9q34. Am J Hum Genet (2000) 1.91
X-linked mental retardation. J Med Genet (1974) 1.91
Dizygous twinning and premature menopause in fragile X syndrome. Lancet (1994) 1.90
Association of triadin with the ryanodine receptor and calsequestrin in the lumen of the sarcoplasmic reticulum. J Biol Chem (1995) 1.86
Fragile-X syndrome: unique genetics of the heritable unstable element. Am J Hum Genet (1992) 1.85
Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma. Int J Cancer (1989) 1.85
Morphoregulatory activities of NCAM and N-cadherin can be accounted for by G protein-dependent activation of L- and N-type neuronal Ca2+ channels. Cell (1991) 1.85
Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. J Virol (2001) 1.85
Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol (1993) 1.83
Human muscle neural cell adhesion molecule (N-CAM): identification of a muscle-specific sequence in the extracellular domain. Cell (1987) 1.81
Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature (1988) 1.81
A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell (1994) 1.80
Identification and characterization of the high affinity [3H]ryanodine receptor of the junctional sarcoplasmic reticulum Ca2+ release channel. J Biol Chem (1987) 1.80
Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol (1996) 1.79